This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Baxter International (BAX) Disappoint in Q4 Earnings?
by Zacks Equity Research
Baxter International Inc. (BAX) is scheduled to report fourth-quarter 2016 earnings on Feb 1, before the opening bell.
The Zacks Analyst Blog Highlights: UnitedHealth, Aetna, Molina HealthCare and Centene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, Aetna, Molina HealthCare and Centene
Henry Schein (HSIC) Q4 Earnings: Disappointment in Store?
by Zacks Equity Research
Henry Schein, Inc. (HSIC) is expected to report fourth-quarter 2016 financial numbers on Feb 8, before the opening bell.
Will Trump's Executive Order Rattle Healthcare Market?
by Zacks Equity Research
Donald Trump has signed an executive order in relation to the Affordable Care Act (ACA) or the more popularly called Obamacare.
Teladoc (TDOC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Telehealth provider, Teladoc Inc. (TDOC ) is scheduled to report fourth-quarter and full-year 2016 results on Jan 27.
4 Reasons Why WellCare Health Stock is a Great Pick Now
by Zacks Equity Research
In spite of the possibility of the reform affecting WellCare Health's business, the company remains an attractive pick for investors.
AmerisourceBergen (ABC) Q1 Earnings: Will It Disappoint?
by Zacks Equity Research
AmerisourceBergen Corp. (ABC) is set to report first-quarter fiscal 2017 results on Jan 31, before the opening bell.
C.R. Bard (BCR) to Report Q4 Earnings: A Surprise in Store?
by Zacks Equity Research
Delving deeper into the fundamentals of C.R. Bard (BCR), let's see how things are shaping up prior to this quarter.
Is a Surprise in Store for Hologic (HOLX) in Q1 Earnings?
by Zacks Equity Research
Hologic Inc. (HOLX) is slated to report first-quarter fiscal 2017 financial results on Feb 1, after the closing bell.
Myriad Genetics (MYGN) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Myriad Genetics, Inc.(MYGN) is expected to report second-quarter fiscal 2017 results on Feb 7, after the closing bell.
IDEXX Laboratories (IDXX) Q4 Earnings: What's in Store?
by Zacks Equity Research
IDEXX Laboratories, Inc. (IDXX) is slated to report fourth-quarter 2016 results on Feb 2, before the opening bell.
Will Boston Scientific (BSX) Pull a Surprise in Q4 Earnings?
by Zacks Equity Research
Boston Scientific Corporation (BSX) is scheduled to report fourth-quarter and full-year 2016 results before the opening bell on Feb 2.
Edward Lifesciences (EW): What's in Store in Q4 Earnings?
by Zacks Equity Research
Edward Lifesciences Corp. (EW) is scheduled to report fourth-quarter and full-year 2016 earnings results after market close on Feb 1, 2017.
Illumina (ILMN) Q4 Earnings: A Beat in Store for the Stock?
by Zacks Equity Research
We expect Illumina Inc (ILMN) to beat expectations when it reports fourth-quarter 2016 results after the closing bell on Jan 31.
UnitedHealth (UNH) Beats on Q4 Earnings, Enrollment Grows
by Zacks Equity Research
UnitedHealth's (UNH) earnings of $2.11 per share, beat the Zacks Consensus Estimate of $2.07. Earnings improved 50.7% year over year.
Coupa Completes Acquisition of Spend360 International
by Zacks Equity Research
Coupa Software Inc. (COUP) recently completed the acquisition of U.K based Spend360 International for an undisclosed amount.
Is Obamacare on its Way Out?
by Arpita Dutt
Healthcare stocks like will remain in focus as the "repeal Obamacare" situation plays out.
Humana (HUM) to Write off Receivables; Updates Guidance
by Zacks Equity Research
Humana Inc. (HUM) recently announced its decision to write off its receivables of $591 million associated with the risk corridor premium stabilization program outstanding as of Sep 30, 2016.
Humana, FullWell to Enhance Value-Based Care in Colorado
by Zacks Equity Research
Humana Inc. (HUM) recently announced that it has entered in to a value-based agreement with population health leader, FullWell
Molina Helathcare's (MOH) 2017 Star Quality Ratings Raised
by Zacks Equity Research
Molina Healthcare Inc.'s (MOH) eligible health plans have either been raised or have remained unchanged in terms of the 2017 Star Ratings by Centers for Medicare & Medicaid Services ("CMS").
Coupa Software (COUP) Stock Up on Lower Y/Y Loss in Q3
by Zacks Equity Research
Coupa Software Inc.'s (COUP) share price surged more than 10% after hours, after the company reported impressive third-quarter fiscal 2017 results.
5 Healthcare Stocks to Buy Now
by Jeremy Mullin
Once Obamacare was put in place, healthcare companies positioned themselves to be the benefactors of the new age of health care.
Health Insurance Stock Outlook - Feb. 2016
by Zacks Equity Research
The ACA law has been in place for almost six years now, and has mostly been absorbed by the industry.
Will Election 2016 Mean New Challenges for Health Insurers?
by Zacks Equity Research
Presidential candidates are looking at ways to fine tune the provisions of the healthcare legislation, which, if implemented, will see insurers reworking their business strategies.
4 Health Insurers Set to Beat Q3 Earnings
by Zacks Equity Research
The year 2015 has been strong for health insurers.